Higher vs. Lower Dose Heparin for PCI
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Higher Dose UFH, Lower Dose UFH.
- Who it may be relevant to
- Registry conditions: Cardiovascular Diseases, Percutaneous Coronary Intervention. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized Trial of Higher vs. Lower Dose Heparin for PCI
Overview
HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).
Detailed description
The primary objective of HD PCI is to compare the effect of a policy of higher dose heparin (100 U/kg) use to a policy of lower dose heparin (70 U/kg) use on death, myocardial infarction (MI) or target vessel revascularization (TVR) in patients undergoing elective percutaneous coronary intervention (PCI).
Interventions
- Drug Higher Dose UFH
Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures - Drug Lower Dose UFH
Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
Primary outcome measures
- Number of Participants with any of the following: death, myocardial infarction or target vessel revascularization [Time frame: up to 30 days after PCI]
Secondary outcome measures (2)
- Number of Participants with major bleeding [Time frame: up to 30 days after PCI]
- Number of Participants with any of the following: death, myocardial infarction, target vessel revascularization or major bleeding [Time frame: up to 30 days after PCI]
Eligibility criteria
Inclusion criteria
\- Patients undergoing elective PCI
Exclusion criteria
- Age <18 years
- Planned chronic total occlusion PCI
- Non-resident precluding follow up through local registries
Hospital (Cluster) Eligibility Criteria
Hospitals will be eligible to participate if they meet the following criteria:
- Submit PCI procedure data to a compatible registry that is able to provide data for the trial
- Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Canada · 1 center
- Hamilton Health Sciences, General Hospital — Hamilton
Publications
- d'Entremont MA, Lee SF, Wijeysundera HC, Tsang MB, Amlani S, Wassef A, Lavi S, So DYF, Betz J, Tyrwhitt J, Graham J, Cantor WJ, Bagherli A, Vijayaraghavan R, Jolly SS. Design and rationale of the HD PCI trial: A cluster randomized crossover trial of higher vs. lower dose heparin for elective percutaneous coronary intervention. Am Heart J. 2026 Apr;294:107330. doi: 10.1016/j.ahj.2025.107330. Epub 2 PMID 41443541
Identifiers
NCT: NCT04049591 · HD PCI